Therapy of Complicated Intra-Abdominal Infections With Moxifloxacin or Ertapenem

Summary

A study to compare the safety and efficacy of moxifloxacin to ertapenem in patients with intra-abdominal infections.

Timeline

Start

2006-07

Primary completion

2009-02

Completion

2009-02

Outcome

Met primary endpoint

paper Moxifloxacin was non-inferior to ertapenem regarding clinical success [89.5% (315/352) versus 93.4% (324/347); 95% confidence PMID 23153963 ↗

paper interval (CI) -7.9%, 0.4%]. PMID 23153963 ↗

Publications

• Results De Waele JJ, Tellado JM, Alder J, Reimnitz P, Jensen M, Hampel B, Arvis P. Randomised clinical trial of moxifloxacin versus ertapenem in complicated intra-abdominal infections: results of the PROMISE study. Int J Antimicrob Agents. 2013 Jan;41(1):57-64. doi: 10.1016/j.ijantimicag.2012.08.013. Epub 2012 Nov 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Ertapenem	Small molecule	1 g	Intravenous
Subject	Moxifloxacin	Small molecule	400 mg	Intravenous

Indications